Christopher Carthron

6505--Tacrolimus Capsules

The Department of Veterans Affairs, through the National Acquisition Center, is seeking an unrestricted procurement for Tacrolimus Capsules to support multiple federal health agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This commercial item procurement, conducted under FAR Part 12, will be awarded to a single responsible offeror capable of providing an uninterrupted source of supply. The contract structure consists of a one-year base period with four pre-priced one-year option periods. Distribution of the pharmaceuticals will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. The scope of work includes the supply of three specific strengths of Tacrolimus capsules, with estimated annual requirements of 51,904 bottles of 0.5mg, 142,788 bottles of 1mg, and 5,207 bottles of 5mg. Strict labeling requirements are mandated, requiring offerors to provide the exact name of the drug as it appears on the label and a unique NDC number. The contractor's label must be the only label on the product, and the practice of affixing labels over existing ones is strictly prohibited. The solicitation is managed by the Enterprise Procurement Office in Hines, Illinois, with a response deadline of September 16, 2026.

Department Of Veterans AffairsIL,

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

Posted Sep 4, 2026

36E79726R0033

Closed

Awarded3

6505--Diltiazem SA Capsules (AB3)

The Department of Veterans Affairs, through the Nac Pharmaceuticals office in Hines, Illinois, is soliciting offers under solicitation number 36E79726R0022 for the supply of Diltiazem extended-release capsules in various strengths—120mg, 180mg, 240mg, 300mg, and 360mg—each packaged in 90-count bottles with unit-of-use labeling. This contract, issued in commercial item format under FAR Part 12 using Standard Form 1449, establishes a five-year ordering period with a base year and four one-year option periods, subject to unilateral government exercise. The estimated annual quantities for each strength remain constant across all years, totaling over 130,000 bottles annually across all line items, with pricing required to include a 0.5% Cost Recovery Fee and capped at the Federal Ceiling Price plus that fee for covered drugs. All products must be FDA-approved, manufactured under current Good Manufacturing Practices, and identified by a unique NDC number specific to the offeror. Packaging must meet stringent specifications including a 120cc cylindrical bottle with a minimum 5.75-inch circumference, a safety-cap that can be converted to a non-safety cap, and labeling space for a 5.25” x 2” label plus 0.5” for bar code, lot number, and expiration date. Each bottle must be compatible with automated dispensing systems such as Opti-fill and Baxter ATC Canisters. All pharmaceuticals must include bar code labeling on the immediate container and external packaging, conforming to GS1-128, HIBCC HIBC, or UPC standards that encode the full NDC, printed at ANSI/ISO/IEC Quality Grade C or higher, with specific requirements for blister packs and ladder orientation to avoid curvature issues. Proposals are evaluated using a lowest price technically acceptable approach, where non-cost factors—including past performance, technical compliance, regulatory certifications, and adherence to packaging and bar coding standards—serve as pass/fail gates. The Government reserves the right to refuse awards if option prices are unbalanced, and evaluation is based on aggregating base and option year prices multiplied by estimated quantities. Offerors must maintain current SAM registration, include UEI, DUNS, and TIN identifiers, and submit a signed SF-1449 with all required representations such as FAR 52.20

Department Of Veterans AffairsIL, USA$10.8M est.

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

36E79726R0022

Awarded

Awarded3

6505--Zonisamide Capsules

The Department of Veterans Affairs National Acquisition Center has issued solicitation number 36E79726R0005 for the procurement of Zonisamide Capsules in 25 mg, 50 mg, and 100 mg strengths. This solicitation seeks to establish a firm-fixed-price, indefinite-delivery, requirements contract covering a one-year base period with four one-year option periods. The contract aims to ensure an uninterrupted supply of these pharmaceutical products to federal healthcare agencies including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers. Deliveries are to be made via established pharmaceutical prime vendor programs, with products packaged in 100-count bottles. Offerors must provide the drug with its exact labeled name and a unique National Drug Code (NDC), and the contractor’s label must be exclusive on the product without any over-labeling. The procurement is conducted under FAR Part 12 as a commercial item acquisition and requires electronic submission of proposals exclusively through SAM.gov, with a submission deadline of December 30, 2025. Key compliance points include strict adherence to packaging and labeling requirements aligned with FDA regulations and federal pharmaceutical standards, ensuring quality and traceability through exclusive NDC labeling. The contract emphasizes reliability and continuous supply over price alone, suggesting a trade-off evaluation approach. Inspection responsibilities rest primarily with the contractor to guarantee conformance before delivery, with acceptance likely occurring at federal distribution centers though specifics are not delineated. No small business set-asides or socio-economic preference designations apply, and no explicit evaluation factors, weights, or certifications are disclosed in the current solicitation notice. The contracting office, located in Hines, Illinois, will oversee administration, with Christopher Carthron serving as Contract Specialist and primary point of contact. The solicitation prohibits paper submissions and over-labeling practices and underscores electronic access to all solicitation documents via sam.gov, reflecting a streamlined acquisition designed to maintain continuous pharmaceutical availability to federal healthcare entities.

Department Of Veterans AffairsIL, USA$4.2M est.

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

36E79726R0005

Awarded

Federal4

6505--Ustekinumab Pens/Syringes or Biosimilar

The Department of Veterans Affairs (VA) National Acquisition Center plans to issue Request for Proposal (RFP) number 36E79726R0006 for the procurement of Ustekinumab pens/syringes or FDA-approved biosimilar products. This unrestricted solicitation encompasses supply for multiple federal healthcare entities, including the VA (covering Consolidated Mail Order Pharmacies and State Veterans Homes), Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers. The contract will be awarded to one responsible offeror capable of providing a reliable and uninterrupted source of supply for the specified items. The award will be for a one-year base period with four pre-priced option years, totaling a potential five years of contract performance. Distribution of awarded products is required exclusively through the VA's and DoD's Pharmaceutical Prime Vendor Programs. The solicitation includes three primary product line items differentiated by strength and packaging formats (syringe and vial), with estimated annual requirements ranging from approximately 2,900 to 45,700 units depending on the dosage form. Offerors must provide the exact drug name as it appears on the label, carry a unique National Drug Code (NDC) exclusive to their product, and must not relabel or overlay any existing manufacturer labeling. If both syringe and vial forms exist commercially for a given strength, offerors are required to offer both at the same price with no price differentiation allowed. Biosimilar products must be FDA-licensed under the Public Health Service Act (42 U.S.C. § 262), must meet all statutory biosimilarity criteria, and be listed in the FDA’s Purple Book as comparable to the innovator product. The procurement follows commercial item acquisition procedures under FAR Part 12 with the solicitation to be issued electronically via SAM.gov around January 12, 2026, and proposal submissions closing by January 27, 2026. No paper copies or telephone requests for solicitation documents will be entertained, emphasizing electronic access and submission. Christopher Carthron is the designated Contract Specialist and sole point of contact for all procurement communications. Specific details on pricing, evaluation criteria, and inspection/acceptance locations are not provided in the pre-solicitation notice, although standard FDA regulatory compliance and labeling requirements form key performance and quality standards.

Department Of Veterans AffairsIL,

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

Posted Feb 6, 2026

unrestricted36E79726R0006

Closed

Federal1

6505--Oxybutynin CL SA Tablets

The Department of Veterans Affairs, through its National Acquisition Center, is issuing a solicitation for Oxybutynin Cl (Controlled Release, Sustained Action) Tablets, targeting multiple government agencies including VA, DoD, BOP, IHS, and FHCC. The procurement aims to secure a reliable supply of this medication for an initial one-year contract period, with options to extend for four additional years. The contract will be awarded to a responsible offeror capable of providing the specified drug in various dosages and bottle sizes, with detailed quantities outlined for each year. The solicitation emphasizes the need for offerors to include precise drug names, unique NDC numbers, and pricing that accounts for a 0.5% Cost Recovery Fee. The procurement process is unrestricted, with opportunities for small business participation, and all documents, amendments, and related information will be accessible via sam.gov. The deadline for submitting quotations is November 5, 2025, with the solicitation expected to be issued electronically around October 31, 2025. The contract will facilitate distribution through VA and DoD Pharmaceutical Prime Vendor Programs, ensuring a continuous supply of this medication to support the healthcare needs of veterans and other federal agencies.

Department Of Veterans AffairsIL,

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

Posted Oct 22, 2025

36E79725R0062

Closed

Federal3

6505--Ustekinumab or Biosimilar Syringes/Vials

The Department of Veterans Affairs National Acquisition Center is preparing to issue Request for Proposal (RFP) 36E79725R0045 for the procurement of Ustekinumab syringes and vials, including biosimilar products that meet FDA licensure and Purple Book listing criteria. This unrestricted contract will supply multiple federal agencies including the VA (covering Consolidated Mail Order Pharmacies and State Veterans Homes), Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded to a single responsible offeror capable of providing a continuous supply of the required Ustekinumab products. The contract period is for one base year plus four one-year option periods, and the items will be distributed via VA and DoD Pharmaceutical Prime Vendor Programs. The NAICS code is 325412, and the solicitation will be issued electronically in commercial item format around July 3, 2025, with the closing date initially set for July 17, 2025 but later extended to July 31, 2025. The procurement includes three specific line items of Ustekinumab, covering different dosage forms and package sizes, with estimated annual quantities updated to reflect an increase for the 90mg/1ml syringe/vial to 45,763 units. Offerors are required to submit pricing for both syringe and vial forms if both are commercially available for the same strength, with pricing inclusive of a 0.5% cost recovery fee. Products must bear the offeror’s unique NDC number and label, ensuring no label overlays are permitted. The solicitation allows for participation from all responsible sources, including small business categories such as service-disabled veteran-owned and women-owned businesses. All amendments and solicitation documents are available through SAM.gov, and interested parties are encouraged to monitor the site for updates. Christopher Carthron is the designated point of contact for questions and correspondence related to this acquisition.

Department Of Veterans AffairsIL,

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

Posted Jul 16, 2025

36E79725R0045

Closed

Awarded1

6505--Hydroxychloroquine Tablets

The Department of Veterans Affairs National Acquisition Center is preparing to issue a Request for Proposal (RFP) for the procurement of Hydroxychloroquine Sulfate 200mg Tablets to support multiple federal health agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and the Federal Health Care Center. This unrestricted procurement seeks a single responsible contractor capable of providing a continuous supply of the medication. The contract will have an initial one-year period with four additional one-year options at pre-established prices, with distribution managed through the VA's and DoD's Pharmaceutical Prime Vendor Programs. Suppliers must provide the exact drug name as labeled on the product with a unique National Drug Code (NDC), and contractors are prohibited from relabeling another product. The solicitation, issued under NAICS code 325412, will be released electronically in commercial item format around March 12, 2025, with a closing date of March 26, 2025. Estimated annual demand includes approximately 163,395 bottles of 100-tablet packages and 25,853 bottles of 500-tablet packages. No paper copies of the solicitation will be distributed, and prospective offerors are encouraged to monitor amending documents through the SAM.gov website. All responsible sources may submit proposals for consideration. The contracting officer overseeing this procurement is Chris Carthron, with contact available via email for any inquiries.

Department Of Veterans AffairsIL, USA$14.6M est.

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

36E79725R0022

Awarded Jul 15, 2025

Federal3

6505--Clonidine Patches

The Department of Veterans Affairs National Acquisition Center plans to issue a Request for Proposal (RFP) for the procurement of Clonidine Patches under solicitation number 36E79725R0037. This unrestricted procurement will serve multiple federal agencies including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract aims to ensure a continuous supply of Clonidine Patches in three dosage forms (0.1 mg, 0.2 mg, and 0.3 mg per 24 hours) distributed through respective Pharmaceutical Prime Vendor Programs. The anticipated contract duration includes one base year plus four one-year option periods. Offerors must provide products labeled exclusively with their unique National Drug Code (NDC) and must not apply their label over another. The solicitation will be issued electronically around May 13, 2025, with proposals due by May 27, 2025, and will follow the commercial item acquisition procedures under FAR Part 12. The NAICS code for this procurement is 325412. Estimated annual quantities are approximately 28,788 bottles for the 0.1 mg patch, 32,468 for the 0.2 mg patch, and 36,204 for the 0.3 mg patch. All solicitation documents and future amendments will be available only on SAM.gov. Interested offerors should monitor this site for updates and direct questions to the Contracting Officer, Christopher Carthron.

Department Of Veterans AffairsIL,

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

Posted Jul 8, 2025

36E79725R0037

Closed

Awarded1

6505--Carbidopa/Levodopa SA Tablet

The Department of Veterans Affairs National Acquisition Center plans to issue a Request for Proposal (RFP 36E79725R0008) for procurement of Carbidopa/Levodopa sustained-release tablets to supply the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This contract will involve providing an uninterrupted supply of two tablet strengths—Carbidopa 25mg/Levodopa 100mg and Carbidopa 50mg/Levodopa 200mg—in 100-tablet bottles, with estimated annual quantities of approximately 60,932 and 58,943 bottles respectively. The contract term is one year with four optional one-year extensions, and the distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. Vendors must provide products labeled with a unique NDC number exclusive to their product and avoid relabeling. The solicitation will be issued electronically on or around January 3, 2026, following commercial item acquisition procedures under FAR Part 12, with proposals due by January 17, 2026. The procurement falls under NAICS code 325412, and all responsible offerors may submit proposals for consideration. No paper copies of the solicitation will be provided; all documents and amendments will be accessible through the SAM.gov system. For questions and communications, the designated contracting officer is Christopher Carthron, who can be contacted via email or phone. Interested vendors are encouraged to monitor SAM.gov for updates and any changes to the solicitation.

Department Of Veterans AffairsIL, USA$10.8M est.

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

36E79725R0008

Awarded Apr 8, 2025

Awarded1

6505--Calcitonin Gene-Related Peptides (CGRP)

The contract pertains to the solicitation titled "6505--CGRP Calcitonin Gene-Related Peptides," issued by Nac Pharmaceuticals, located in Hines, Illinois. The solicitation was posted on October 15, 2024, with an original response deadline that has been extended to October 31, 2024, at 7:30 PM Central Time. The purpose of this contract involves the procurement or research related to calcitonin gene-related peptides, which are likely relevant to medical or pharmaceutical applications. The contract is managed by a designated Contract Specialist, Christopher Carthron, who can be contacted via email for further details. The contract falls under NAICS code 325412, which covers pharmaceutical and medicine manufacturing, indicating its focus on pharmaceutical products or related research. The extension of the offer due date signifies a possible adjustment to accommodate additional responses or to ensure comprehensive participation from potential vendors or collaborators.

Department Of Veterans AffairsIL, USA$100.5M est.

NAICS

325412

Pharmaceutical Preparation Manufacturing

PSC

6505

Medical, Dental, and Veterinary Equipment and Supplies

36E79724R0030

Awarded Jan 13, 2025